Peer-reviewed veterinary case report
Toceranib treatment outcomes for dogs with aortic body tumors
By Giovanna M. Coto et al.·Published in Frontiers in Veterinary Science·2021·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with aortic body tumors, known as chemodectomas, were treated with a medication called toceranib phosphate. Out of 27 dogs, 89% showed improvement, either through complete or partial remission, or stable disease lasting more than 10 weeks. The average survival time for dogs treated with toceranib alone was about 478 days, which was similar to those receiving additional treatments. While this study suggests that toceranib can be beneficial for dogs with these tumors, more research is needed to confirm its effectiveness.
People also search for: dog heart tumor treatment · chemodectoma in dogs · toceranib phosphate for dogs · dog cancer survival rates · canine aortic body tumor prognosis
Abstract
Aortic body tumors, specifically chemodectomas, are the second most common type of canine cardiac tumor; however, information about treatment is currently lacking. This study included dogs with a presumptive or definitive diagnosis of an aortic body chemodectoma that underwent treatment with toceranib phosphate. Cases were solicited via the American College of Veterinary Internal Medicine Cardiology, Internal Medicine, and Oncology listservs using an electronic survey. Cox multivariate analysis of factors potentially impacting survival time was completed. Twenty-seven (27) cases were included in analysis. The clinical benefit rate (complete remission, partial remission, or stable disease >10 weeks) was 89%. A median survival time of 478 days was found for those receiving toceranib alone (n = 14), which was not statistically different from those treated with additional modalities (521 days). No factors evaluated statistically impacted outcome. Further, prospective studies are warranted to evaluate the use of toceranib for the treatment of canine aortic body chemodectomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/33614771